Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Antineoplastic and immunomodulating drugs
Rigosertib
Другие языки:

    Rigosertib

    Подписчиков: 0, рейтинг: 0
    Rigosertib
    Rigosertib.svg
    Names
    IUPAC name
    (2-Methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethene-1-sulfonyl]methyl}phenyl)glycine
    Systematic IUPAC name
    (2-Methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethene-1-sulfonyl]methyl}anilino)acetate
    Other names
    ON-01910
    Identifiers
    3D model (JSmol)
    ChEBI
    ChEMBL
    ChemSpider
    KEGG
    PubChem CID
    UNII
    • InChI=1S/C21H25NO8S/c1-27-15-10-19(29-3)16(20(11-15)30-4)7-8-31(25,26)13-14-5-6-18(28-2)17(9-14)22-12-21(23)24/h5-11,22H,12-13H2,1-4H3,(H,23,24)/b8-7+
      Key: OWBFCJROIKNMGD-BQYQJAHWSA-N
    • : COC1=C(C=C(C=C1)CS(=O)(=O)/C=C/C2=C(C=C(C=C2OC)OC)OC)NCC(=O)O
    Properties
    C21H25NO8S
    Molar mass 451.49 g·mol−1
    Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

    Rigosertib (ON-01910 sodium salt, with Estybon as trade name) is a synthetic benzyl styryl sulfone in development by Onconova Therapeutics. Rigosertib is in phase III clinical trials for the treatment of chronic myelomonocytic leukemia.

    Its geometrical isomer (Z)-ON 01910·Na has less cytotoxicity on cancer cells.

    Mechanism

    Rigosertib is a microtubule-destabilizing agent.



    Новое сообщение